Corcept Therapeutics Inc. (CORT) is a leading pharmaceutical company primarily focused on the development and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders caused by cortisol dysregulation. The company is committed to breakthrough scientific research to transform patient lives and has made significant strides in medicine through their proprietary platform based on the pharmacological modulation of cortisol activity.
The company was founded in 1998 and publicly traded on NASDAQ. It is based in the heart of Silicon Valley, Menlo Park, California. Despite being relatively smaller compared to the major global pharmaceutical companies, Corcept has consistently punched above its size, making significant strides in drug development and clinical research.
Corcept Therapeutics has a flagship product called Korlym® (mifepristone), which was first to be approved by the U.S. Food and Drug Administration (FDA) in 2012. This flagship product is used for the treatment of hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome.
Aside from Korlym, Corcept is also in various stages of clinical trials for additional drug candidates aimed at addressing serious disorders. One of the most promising is Relacorilant, which treats patients with Cushing's syndrome but does so without the side effects associated with Korlym. Other notable drugs in Corcept's pipeline include drugs for the treatment of solid tumors, triple-negative breast cancer, and ovarian cancer, among others.
Because of its impressive work in the stress hormone cortisol, Corcept Therapeutics has truly established itself as a major force in the medical industry. The company’s ongoing pre-clinical and clinical programs demonstrate its commitment to innovation, improved patient outcome, and addressing unmet medical needs.
Despite its success in drug discovery and development, Corcept Therapeutics has not been without its challenges. Pricing pressures, regulatory hurdles, patent cliffs, and competition from larger pharmaceutical companies have posed significant challenges. However, the company has proven resilient, displaying a strong commitment to research and development, as well as a strategic skill for navigating the challenging pharmaceutical industry.
In summary, Corcept Therapeutics Inc. (CORT) is an innovative biopharmaceutical company dedicated to providing groundbreaking treatments for diseases associated with cortisol dysregulation. The company is noted for its pioneering research and the successful launch of its lead product Korlym and is progressive towards contributing more to the medical industry.